Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at up to approximately $25 million by the U.S. Department of State to supply TROBIGARD™ (Atropine Sulfate [2mg]/Obidoxime Chloride [220mg]) auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning. Trobigard is designed for intramuscular self- or buddy-administration of atropine sulfate and obidoxime chloride for pre-hospital intervention.
{iframe}https://globenewswire.com/news-release/2017/10/04/1140537/0/en/Emergent-BioSolutions-Awarded-U-S-Department-of-State-Contract-Valued-at-Up-to-25-Million-to-Supply-Nerve-Agent-Antidote-Auto-Injector.html{/iframe}